| Title |
Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer
|
|---|---|
| Published in |
International Journal of Clinical Oncology, February 2009
|
| DOI | 10.1007/s10147-008-0797-8 |
| Pubmed ID | |
| Authors |
Makiko Ono, Masashi Ando, Mayu Yunokawa, Eriko Nakano, Kan Yonemori, Koji Matsumoto, Tsutomu Kouno, Chikako Shimizu, Kenji Tamura, Noriyuki Katsumata, Yasuhiro Fujiwara |
| Abstract |
Recently, a high rate of brain metastases has been reported among patients with human epidermal growth factor receptor (HER2)-overexpressing metastatic breast cancer who were treated with trastuzumab. The present study examined risk factors for the development of brain metastasis in patients with HER2-overexpressing breast cancer who were treated with trastuzumab. |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 3% |
| Unknown | 37 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 24% |
| Student > Ph. D. Student | 8 | 21% |
| Student > Bachelor | 4 | 11% |
| Other | 3 | 8% |
| Student > Postgraduate | 3 | 8% |
| Other | 6 | 16% |
| Unknown | 5 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 39% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 8% |
| Economics, Econometrics and Finance | 3 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Social Sciences | 2 | 5% |
| Other | 7 | 18% |
| Unknown | 6 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2023.
All research outputs
#3,893,130
of 23,342,092 outputs
Outputs from International Journal of Clinical Oncology
#49
of 928 outputs
Outputs of similar age
#15,119
of 95,423 outputs
Outputs of similar age from International Journal of Clinical Oncology
#1
of 3 outputs
Altmetric has tracked 23,342,092 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 928 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,423 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them